Supplementary Information for

Causal evidence that herpes zoster vaccination prevents a proportion of dementia cases

Correspondence to: pgeldsetzer@stanford.edu

This PDF file includes:

- Materials
- Figs. S1 to S16
- Tables S1 to S4

Materials

Below we list Read version 2 (used for all care processes in primary care electronic health record data) and ICD-10 (used for diagnoses in secondary care records and death certificates) codes for all key variables in our analysis.

Herpes zoster vaccination

Read code	ICD-10 code
65FY. 65FY.1 65FY.11 65FY0 n4v1. n4v4.	Not applicable

Primary and secondary outcomes

Dementia of any type

				Read	d code									ICD-	·10 code				
1461	38C13	3AE3.	3AE4.	3AE5.	3AE6.	66h	6AB	8BM02	8CMG2	F00	F00,	F00.	F00'	F000	F001	F002	F003	F004	F007
8CMZ.	8CMZ0	8CMZ1	8CMZ2	8CMZ3	8CSA.	9hD	9hD0.	9hD1.	9Ou	F008	F009	F00A	F00X	F01	F01.	F010	F011	F012	F013
9Ou1.	9Ou2.	9Ou3.	9Ou4.	9Ou5.	A411.	A4110	E00	E001	E0011	F018	F019	F01X	F02	F02.	F020	F021	F022	F023	F025
E002	E0097	E000.	E001.	E0010	E0011	E0012	E0013	E001z	E002.	F028	F029	F02X	F03	F03.	F030	F031	F032	F033	F034
E0020	E0021	E002z	E003.	E004.	E004.1	E004.11	E0040	E0041	E0042	F038	F039	F03X	F051	G30	G30.	G300	G301	G308	G309
E0043	E004z	E012.	E012.1	E0120	E02y1	E041.	Eu00.	Eu000	Eu00011	G30D	G30X	G310	G311	G318	1673				
Eu001	Eu00112	Eu0012	Eu002	Eu00z	Eu00z1	Eu00z11	Eu01.	Eu010	Eu011										
Eu012	Eu013	Eu01y	Eu01z	Eu02.	Eu020	Eu021	Eu022	Eu023	Eu025										
Eu02y	Eu02z	Eu02z13	Eu02z14	Eu02z3	Eu02z4	Eu041	Eu106	Eu1061	Eu107										
Eu10711	F110.	F1100	F1101	F111.	F112.	F116.	F118.	F1181	F11x2										
F11x7	F11x9	F11y2	F21y2	Fyu30															

Vascular dementia

	Read code 04. E004.1 E004.11 E0040 E0041 E0042 E0043 E004z Eu01. Eu													ICD-	10 code				
E004. Eu011	E004.1 Eu01y		E0040 F11x2	E0041 F21y2	E0042	E0043	E004z	Eu01.	Eu010	F01	F01.	F010	F011	F012	F013	F018	F019	F01X	1673

Alzheimer's disease

	Read code								ICD	-10 code				
Eu00. Eu000 Eu00011 Eu001 F110. F1100 F1101 F112.	Eu00112 Eu0012 Eu002 Fyu30	Eu00z	Eu00z1	Eu00z11	F00 F008 G30D	F00, F009 G30X	F00. F00A	F00X	F000 G30	F001 G30.	F002 G300	F003 G301	F004 G308	F007 G309

Dementia of unspecified type

				Rea	d code									ICD-	-10 code				
1461 8CMZ. 9Ou1.	38C13 8CMZ0 9Ou2.	3AE3. 8CMZ1 9Ou3.	3AE4. 8CMZ2 9Ou4.	3AE5.	3AE6. 8CSA. A411.	66h 9hD A4110	6AB 9hD0. E00	8BM02 9hD1. E001	8CMG2 9Ou E0011	F02 F03 F051	F02. F03. G310	F020 F030 G311	F021 F031 G318	F022 F032	F023 F033	F025 F034	F028 F038	F029 F039	F02X F03X
E002 E0020 Eu013 Eu02z14 F118.	E0097 E0021 Eu02. Eu02z3 F1181	E002z Eu020 Eu02z4	Eu041	E0010 E012. Eu022 Eu106 F11y2	E0011 E012.1 Eu023 Eu1061	E0012 E0120 Eu025 Eu107	E0013 E02y1 Eu02y Eu1071	E001z E041. Eu02z 1 F111.	E002. Eu012 Eu02z13 F116.										

New prescription of donepezil hydrochloride, galantamine, rivastigmine, or memantine hydrochloride

				Rea	id code					ICD-10 code
dB1	dB11.	dB12.	dB13.	dB14.	dB15.	dB16.	dB17.	dB18.	dB19.	Not applicable
dy1	dy11.	dy12.	dy13.	dy14.	dy15.	dy16.	dy1y.	dy1z.	dy21.	
dy22.	dy23.	dy24.	dy25.	dy26.	dy27.	dy28.	dy29.	dy2A.	dy2B.	
dy2C.	dy2D.	dy2E.	dy2F.	dy2J.	dy2K.	dy2L.	dy2M.	dy2N.	dy20.	
dy2R.	dy2S.	dy31.	dy32.	dy33.	dy34.	dy35.	dy36.	dy37.	dy38.	
dy39.	dy3B.	dy3C.	dy3D.	dy3K.	dy3L.	dy3M.	dy3t.	dy3u.	dy3v.	
dy3w.	dy3x.	dy3y.	dy3z.							

<u>Shingles</u>

				Read	d code									ICD-	10 code			
A53	A531	A5311	A530.	A531.	A531.1	A531.11	A5310	A5311	A53111	B020	B021	B022	B023	B027	B028	B029	B02X	
A5312	A5313	A5314	A5315	A53151	A53151	1 A531z	A532.	A5320	A5321									
A5322	A5323	A5324	A532z	A53x.	A53x0	A53x1	A53xz	A53y.	A53z.									
AyuA4	AyuA5	F0112	F0309	F300.	F3744	F5016	HNG004	11HNG006	30									
	A4 AyuA5 F0112 F0309 F300. F3744 F5016 HNG0041HNG0060																	

Postherpetic neuralgia

				Read code	ICD-10 code
A531.	A5312	A5313	A5315	A53151 A531511 F300.	B022

Outcomes for negative control outcome analyses Ischemic heart disease

00. G301.	3 G33 G3010		G3012	Read code G311 G313 G33 G30 G3012 G3014 G3015 G304 G													
	G3010			O30 17	G3015	G304	G305	121	I21.	1210	1211	1212	1213	1214	1218	1219	I21X
		G3011	G301z	G302.	G303.	G304.	G305.	122	122.	1220	1221	1228	1229	122X	1230	1231	1232
07. G307	G3071	G308.	G309.	G30A.	G30B.	G30X.	G30X0	1233	1234	1235	1236	1238	1240	1241	1248	1249	124X
0y0 G30y2	G30yz	G30z.	G31	G310.	G311.	G311.11	G311.13										
11.3 G311	G3111	G3112	G3113	G3114	G3115	G311z	G312.										
1y0 G31y0	99 G31y1	G31y2	G31y3	G31yz	G32	G3211	G35										
51. G353.	G35X.	G36	G360.	G361.	G362.	G363.	G364.										
66. G37	G38	G380.	G381.	G384.	G38z.	G39	G3y										
11 11 15 15 1	1.3 G3110 /0 G31y0 1. G353.	I.3 G3110 G3111 /0 G31y099 G31y1 I. G353. G35X.	70 G30y2 G30yz G30z. 1.3 G3110 G3111 G3112 70 G31y099 G31y1 G31y2 1. G353. G35X. G36	70 G30y2 G30yz G30z. G31 1.3 G3110 G3111 G3112 G3113 70 G31y099 G31y1 G31y2 G31y3 1. G353. G35X. G36 G360.	70 G30y2 G30yz G30z. G31 G310. 1.3 G3110 G3111 G3112 G3113 G3114 70 G31y099 G31y1 G31y2 G31y3 G31yz 1. G353. G35X. G36 G360. G361.	70 G30y2 G30yz G30z. G31 G310. G311. 1.3 G3110 G3111 G3112 G3113 G3114 G3115 70 G31y099 G31y1 G31y2 G31y3 G31yz G32 1. G353. G35X. G36 G360. G361. G362.	70 G30y2 G30yz G30z. G31 G310. G311. G311.11 1.3 G3110 G3111 G3112 G3113 G3114 G3115 G311z 70 G31y099 G31y1 G31y2 G31y3 G31yz G32 G3211 1. G353. G35X. G36 G360. G361. G362. G363.	70 G30y2 G30yz G30z. G31 G310. G311. G311.11 G311.13 1.3 G3110 G3111 G3112 G3113 G3114 G3115 G311z G312. 70 G31y099 G31y1 G31y2 G31y3 G31yz G32 G3211 G35 1. G353. G35X. G36 G360. G361. G362. G363. G364.	70 G30y2 G30yz G30z. G31 G310. G311. G311.11 G311.13 1.3 G3110 G3111 G3112 G3113 G3114 G3115 G311z G312. 70 G31y099 G31y1 G31y2 G31y3 G31yz G32 G3211 G35 1. G353. G35X. G36 G360. G361. G362. G363. G364.	70 G30y2 G30yz G30z. G31 G310. G311. G311.11 G311.13 1.3 G3110 G3111 G3112 G3113 G3114 G3115 G311z G312. 70 G31y099 G31y1 G31y2 G31y3 G31yz G32 G3211 G35 1. G353. G35X. G36 G360. G361. G362. G363. G364.	70 G30y2 G30yz G30z. G31 G310. G311. G311.11 G311.13 1.3 G3110 G3111 G3112 G3113 G3114 G3115 G311z G312. 70 G31y099 G31y1 G31y2 G31y3 G31yz G32 G3211 G35 1. G353. G35X. G36 G360. G361. G362. G363. G364.	70 G30y2 G30yz G30z. G31 G310. G311. G311.11 G311.13 1.3 G3110 G3111 G3112 G3113 G3114 G3115 G311z G312. 70 G31y099 G31y1 G31y2 G31y3 G31yz G32 G3211 G35 1. G353. G35X. G36 G360. G361. G362. G363. G364.	70 G30y2 G30yz G30z. G31 G310. G311. G311.11 G311.13 1.3 G3110 G3111 G3112 G3113 G3114 G3115 G311z G312. 70 G31y099 G31y1 G31y2 G31y3 G31yz G32 G3211 G35 1. G353. G35X. G36 G360. G361. G362. G363. G364.	70 G30y2 G30yz G30z. G31 G310. G311. G311.11 G311.13 1.3 G3110 G3111 G3112 G3113 G3114 G3115 G311z G312. 70 G31y099 G31y1 G31y2 G31y3 G31yz G32 G3211 G35 1. G353. G35X. G36 G360. G361. G362. G363. G364.	70 G30y2 G30yz G30z. G31 G310. G311. G311.11 G311.13 1.3 G3110 G3111 G3112 G3113 G3114 G3115 G311z G312. 70 G31y099 G31y1 G31y2 G31y3 G31yz G32 G3211 G35 1. G353. G35X. G36 G360. G361. G362. G363. G364.	70 G30y2 G30yz G30z. G31 G310. G311. G311.11 G311.13 1.3 G3110 G3111 G3112 G3113 G3114 G3115 G311z G312. 70 G31y099 G31y1 G31y2 G31y3 G31yz G32 G3211 G35 1. G353. G35X. G36 G360. G361. G362. G363. G364.	70 G30y2 G30yz G30z. G31 G310. G311. G311.11 G311.13 1.3 G3110 G3111 G3112 G3113 G3114 G3115 G311z G312. 70 G31y099 G31y1 G31y2 G31y3 G31yz G32 G3211 G35 1. G353. G35X. G36 G360. G361. G362. G363. G364.

Chronic obstructive pulmonary disease

				Rea	d code									ICD	-10 code				
H3	H31	H310.	H3100	H310z	H311.	H3110	H3111	H311z	H312.	J410	J411	J418	J41X	J42	J42X	J43	J43.	J430	J431
H3120	H3121	H3123	H312z	H313.	H31y.	H31y1	H31yz	H31z.	H32	J432	J438	J439	J43X	J44	J44.	J440	J441	J444	J445
H320.	H3200	H3201	H3202	H3203	H320z	H321.	H322.	H32y.	H32y0	J448	J449	J44X							
H32y1	H32y2	H32yz	H32z.	H36	H37	H38	H3y	H3z											
	-						-												

<u>Stroke</u>

				Read	code									ICD-	-10 code				
F423.	F4231	F4238	F423811	G60	G600.	G601.	G602.	G603.	G604.	H341	1600	1601	1602	1603	1604	1605	1606	1607	1608
G605.	G606.	G60X.	G60z.	G61	G611	G6111	G6112	G612-	5(G610.	1609	160X	I610	I611	1612	1613	1614	1615	1616	I618
G611.	G612.	G613.	G614.	G615.	G616.	G617.	G618.	G619.	G61X.	I619	161X	163	1630	1631	1632	1633	1634	1635	1636
G61X0	G61X1	G61z.	G63	G630.	G631.	G631.1	G632.	G633.	G634.	1638	1639	163X	164	164.	1640	1644	1649	164X	
G63y.	G63y0	G63y1	G63z.	G64	G641	G6411	G642	G640.	G6400										
G641.	G6410	G64z.	G64z.12	G64z.2	G64z0	G64z1	G64z2	G64z3	G64z4										
G66	G661	G6611	G6612	G6613	G662	G663		G660.	G661.										
G662.	G663.	G664.	G665.	G666.	G667.	G668.	G669.												

Lower respiratory tract infection

		*		Read	d code		- V							ICD-	-10 code		***		
16L	1J72.	1J72.1	1J72.11	1JX	1W0	A33	A330.	A331.	A33y.	A370	A371	A378	A379	A37X	B012	B052	B250	J041	J042
A33yz	A33z.	A521.	A54x4	A730.	A7850	A795.	A7951	A7952	A7953	J100	J101	J108	J10X	J11	J110	J111	J118	J11X	J120
A7954	A7955	A7y00	AB24.	AB405	Ayu39	Ayu3A	Ayu3U	AyuDC	H0	J121	J122	J123	J128	J129	J13	J13X	J14	J14X	J150
H06	H060.	H060.1	H060.11	H0600	H0601	H0602	H0603	H0604	H0605	J151	J152	J153	J154	J155	J156	J157	J158	J159	J160
H0606	H0607	H0608	H0609	H060A	H060B	H060C	H060D	H060E	H060F	J168	J17	J170	J171	J172	J173	J178	J17X	J18	J180
H060v	H060w	H060x	H060z	H061.	H0610	H0611	H0612	H0613	H0614	J181	J182	J188	J189	J180	J18X	J200	J201	J202	J203
H0615	H0616	H0617	H061z	H062.	H06z.	H06z0	H06z01	H06z011	H06z1	J204	J205	J206	J207	J208	J209	J20X	J210	J211	J218
H06z11	H06z111	H06z112	H06z12	H06z2	H07	H2	H2SHF	l₁H20	H200.	J219	J21X	J22	J22#	J220	J229	J22X	J22Y	J440	J851
H201.	H202.	H203.	H204.	H20y.	H20y0	H20z.	H21	H22	H221	J860	J869	P230	P231	P232	P233	P234	P235	P236	P238
H220.	H221.	H222.	H223.	H2230	H224.	H22y.	H22y0	H22y1	H22y2	P239	U049								
H22y3	H22yX	H22yz	H22z.	H23	H230.	H231.	H232.	H233.	H23z.										
H24		H241.	H242.	H243.	H246.	H247.	H2470	H247z	H24y.										
H24y0	H24y2	H24y3	H24y4	H24y7	H24yz	H24z.	H25	H251	H2511										
H2599	H26	H261	H2611	H260.	H2600	H261.	H262.	H263.	H27										
H270.	H2700	H2701	H270z	H271.	H2710	H2711	H271z	H27y.	H27y0										
H27y1	-	H27z.	H27z.1	H27z.11	H27z.12	H27z.2	H28	H29	H2A										
H2A1	H2A11		H2C	H2F	H2Fy.	H2Fz.	H2y	H2z	H2z98										
H30	H301		H3012		H300.	H301.	H302.	H30z.	H31										
H310.	H3100	H3101	H310z	H311.	H3110	H3111	H311z	H312.	H3120										
	H3121	H3122	H312250		H312z	H313.	H31y.	H31y0	H31y1										
H31yz	H31z.	H3y	H3y0.	H3y1.	H3z	H3z11	H47	H471	H4711										
H4799	H470.	H470.1	H470.11		H4701	H4702	H4703	H470312											
H50	H500.	H5000	H5001	H5003	H5004	H5005	H500z	H501.	H5010										
H5011	H5012	H5013	H5014	H5015	H5016	H501z	H50z.	H511.	H5110										
H5111	H5112	H511z	H53	H530.	H5300	H5301	H5302	H5303	H530z										
H5400	H5401	H571.	Hyu1.	Hyu10	Hyu11	Q310.	Q3100	Q3101	Q3102										
Q3103	Q3104	Q3105	Q3106	Q310y	Q310z	SP131	SP132												

Lung cancer

Read code					ICD-	10 code				
Not applicable	C33 C349	C33X C34X	C34	C34,	C340	C341	C342	C343	C344	C348

Pancreatic cancer

Read code				ICD-	·10 code				
Not applicable	C25	C250	C251	C252	C253	C254	C257	C258	C259

Colorectal cancer

Read code					ICD-	10 code				
Not applicable	C18 C188 C218	C18. C189	C180 C18X	C181 C19	C182 C19X	C183 C20	C184 C20X	C185 C210	C186 C211	C187 C212

Breast cancer

Read code					ICD-	10 code				
Not applicable	C50 C50X	C500	C501	C502	C503	C504	C505	C506	C508	C509

Falls

	Read code											ICD-	10 code						
TC	TC1	TC11	TC0	TC00.	TC000	TC001	TC00z	TC01.	TC010	W000	W001	W002	W003	W004	W005	W006	W007	W008	W009
TC011	TC01z	TC02.	TC020	TC021	TC02z	TC0z.	TC1	TC10.	TC11.	W00X	W01	W01.	W010	W011	W012	W013	W014	W015	W016
TC1z.	TC2	TC20.	TC21.	TC22.	TC23.	TC24.	TC27.	TC28.	TC29.	W017	W018	W019	W01X	W020	W021	W022	W023	W024	W025
TC2z.	TC3	TC30.	TC300	TC302	TC305	TC30z	TC31.	TC32.	TC320	W026	W027	W028	W029	W02X	W03	W03.	W030	W031	W032
TC321	TC32z	TC3y.	TC3y0	TC3y1	TC3y2	TC3y3	TC3y4	TC3y6	TC3yz	W033	W034	W035	W036	W037	W038	W039	W03X	W04.	W040
TC3z.	TC4	TC40.	TC41.	TC42.	TC420	TC421	TC42z	TC4y.	TC4y0	W041	W042	W043	W044	W045	W046	W048	W049	W04X	W05
TC4y1	TC4y2	TC4y3	TC4yz	TC4z.	TC5	TC50.	TC51.	TC52.	TC53.	W050	W051	W052	W053	W054	W055	W056	W058	W059	W05X
TC5z.	TC6	TC60.	TC600	TC60y	TC60z	TC6y.	TC6y0	TC6y1	TC6yz	W06	W060	W061	W062	W063	W064	W065	W068	W069	W06X
TC6z.	TC7	TCLO16	TCy	TCy0.	TCyz.	TCz				W07	W070	W071	W072	W073	W074	W075	W076	W077	W078
										W079	W07X	W080	W081	W082	W083	W084	W085	W086	W087
										W088	W089	W08X	W090	W091	W092	W093	W094	W095	W097
										W098	W099	W09X	W10	W100	W101	W102	W103	W104	W105
										W106	W107	W108	W109	W10X	W11	W110	W111	W112	W113
										W114	W115	W116	W117	W118	W119	W11X	W120	W121	W122
										W123	W124	W125	W126	W128	W129	W13	W130	W131	W132
										W133	W134	W135	W136	W137	W138	W139	W13X	W140	W141
										W142	W143	W144	W145	W147	W148	W149	W14X	W150	W152
										W153	W154	W155	W156	W158	W159	W160	W161	W162	W163
										W164	W165	W166	W168	W169	W170	W171	W172	W173	W174
										W175	W176	W177	W178	W179	W17X	W18	W180	W181	W182
										W183	W184	W185	W186	W187	W188	W189	W18X	W19	W19.
										W190	W191	W192	W193	W194	W195	W196	W197	W198	W199
										W190	W19X								

Lower back pain

				Read	code									ICD-	10 code				
16C2.	16C3.	16C4.	16C5.	16C6.	16C8.	16C9.	16CA.	16CZ.	N14	G544	M470	M471	M472	M478	M480	M481	M482	M483	M484
N140.	N140.1	N140.11	N1400	N1401	N1402	N1403	N1404	N1407	N1408	M485	M498	M510	M511	M512	M513	M514	M518	M533	M538
N140A	N140z	N141.	N141.1	N141.11	N142.	N142.1	N142.11	N142.12	N142.13	M540	M541	M543	M544	M990	M991	M992	M993	M994	M995
N142.14	N142.3	N142.4	N1420	N143.	N143.1	N143.11	N144.	N1440	N1441	M996	M997	M998							
N144z	N145.	N145.1	N145.11	N145.12	N145.2	N146.	N1460	N1461	N1463										
N14631	N146311	N1464	N1465	N1466	N146z	N146z1	N146z11	N147.	N1470										
N1471	N1472	N14721	N147211	N147z	N148.	N1480	N1481	N1482	N1483										
N1484	N1485	N1486	N1487	N1488	N1489	N148A	N148B	N148C	N149.										
N14A.	N14X.	N14y.	N14y.1	N14z.	N14z.2														

Diabetes:

Please see separate pdf file (Supplement Materials 2).

Preventive interventions other than zoster vaccination¹

¹ ICD-10 codes are not applicable for these interventions.

Influenza vaccination

				Rea	d code				
65E	65E0.	65E00	65E1.	65E10	65E2.	65E20	65E21	65E22	65E23
65E24	65E3.	65E30	65E4.	65E40	65E5.	65E6.	65E7.	65E8.	65E9.
65EA.	65EB.	65EC.	65ED.	65ED0	65ED1	65ED2	65ED3	65ED4	65ED5
65ED6	65ED7	65ED8	65ED9	65EDA	65EE.	65EE0	65EE1	n47	n471.
n472.	n473.	n476.	n477.	n47a.	n47A.	n47b.	n47B.	n47c.	n47C.
n47d.	n47D.	n47e.	n47E.	n47f.	n47F.	n47g.	n47G.	n47h.	n47H.
n47i.	n47l.	n47j.	n47k.	n47l.	n47m.	n47n.	n47o.	n47p.	n47q.
n47r.	n47u.	n47v.	n47z.						

Pneumococcal vaccination (PPV-23)

				Rea	ad code				
6572.	65720	657K.	657L.	657M.	657N.	657P.	657R.	n4b	n4b1.
n4b2.	n4b4.	n4b9.							

Statin use

				Rea	ad code				
bxd	bxd1.	bxd2.	bxd3.	bxd4.	bxd5.	bxd6.	bxd7.	bxd8.	bxd9.
bxdA.	bxdB.	bxdC.	bxdD.	bxdE.	bxdF.	bxdH.	bxdl.	bxdJ.	bxdK.
bxdu.	bxdv.	bxdw.	bxdx.	bxdy.	bxdz.	bxe	bxe1.	bxe2.	bxe3.
bxe4.	bxe5.	bxe6.	bxe7.	bxe8.	bxg1.	bxg2.	bxg3.	bxg4.	bxg5.
bxgz.	bxi	bxi1.	bxi2.	bxi3.	bxi4.	bxi5.	bxi6.	bxi7.	bxi8.
bxi9.	bxiA.	bxiB.	bxiy.	bxiz.	bxj1.	bxj2.	bxj3.	bxj4.	bxj5.
bxj6.	bxj7.	bxj8.	bxjz.	bxk1.	bxk2.	bxk3.	bxk4.	bxkw.	bxkx.
bxky.	bxkz.								


Use of antihypertensive medications

Please see separate pdf file (Supplement Materials 2).

Breast cancer screening

				Rea	d code				
1A81.	1A82.	1A84.	5371	5372	5373	5376	54L3.	56B1.	585C.
5861	6862	68620	68621	6862Z	6865	7P0F.	7P0F0	7P0F1	7P0F2
7P0Fy	7P0Fz	8HTh.	8HTI.	9N0A.	9N1y9	9Np2.	9OH9.	90HZ.	9Oq8.
L001.	R138.	R1380	R138z	ZV761					

Figs. S1 to S16






Fig. S1: There is exchangeability at baseline across the date-of-birth eligibility cutoff for the ten (other than dementia) leading causes of disability-adjusted life years and mortality in Wales in 2019.^{1,2}

Abbreviations: Coef=coefficient; CI=confidence interval; COPD=chronic obstructive pulmonary disease

¹ Grey dots show the mean value for each 10-week increment in week of birth.

² The analysis of breast cancer diagnoses was restricted to women only.




Fig. S2: No abrupt change at the date-of-birth eligibility cutoff in the probability of having taken up preventive health measures before the start date of the zoster vaccine program.^{1,2,3}

Abbreviations: PPV=pneumococcal polysaccharide vaccine.

¹ Panels A, B, and C are also shown in Fig. 1 in the main manuscript. They have been repeated here for comprehensiveness as flu vaccine uptake, PPV uptake, and statin use also constitute preventive health measures.

² Breast cancer screening participation was defined as having a record of referral to, attendance at, or a report from "breast cancer screening" or mammography. The analysis of breast cancer screening participation was restricted to women only.

³ Grey dots show the mean value for each 10-week increment in week of birth.




Fig. S3: Effect estimates of being eligible (A) and having received the zoster vaccine (B and C) on having at least one shingles diagnosis using local squared regression instead of local linear regression. 1,2,3,4,5

¹ Triangles (rather than points) depict our primary specification.

² Red (as opposed to white) fillings denote statistical significance (p<0.05).

³ With "grace periods" we refer to time periods since the index date after which follow-up time is considered to begin to allow for the time needed for a full immune response to develop after vaccine administration.

⁴ Grey vertical bars depict 95% confidence intervals.

⁵ Grey dots show the mean value for each 10-week increment in week of birth.




Fig. S4: Point estimates for the effect of the zoster vaccine on at least one shingles diagnosis and new dementia diagnoses across different bandwidth specifications. 1,2,3,4,5

Abbreviations: MSE=mean-squared error

¹ The bandwidth is the window (in weeks) in participants' date of birth that is drawn around the September 2 1933 eligibility threshold. The shorter the bandwidth is, the wider is the 95% confidence interval.

² 95% confidence intervals are not symmetrical around the point estimate because we used robust bias-corrected confidence intervals¹.

³ The MSE-optimal bandwidth is 90.6 and 93.0 weeks on either side of the threshold for the dementia and shingles outcome, respectively.

⁴ White points depict statistically insignificant point estimates (p>0.05).

⁵ Grey vertical bars depict 95% confidence intervals.




Fig. S5: Effect estimates of being eligible (A) and having received the zoster vaccine (B and C) on having at least one diagnosis of postherpetic neuralgia (PHN) during the follow-up period. 1,2,3,4,5

¹ Triangles (rather than points) depict our primary specification.

² Red (as opposed to white) fillings denote statistical significance (p<0.05).

³ With "grace periods" we refer to time periods since the index date after which follow-up time is considered to begin to allow for the time needed for a full immune response to develop after vaccine administration.

⁴ Grey vertical bars depict 95% confidence intervals.

⁵ Grey dots show the mean value for each 10-week increment in week of birth. Abbreviations: PHN=postherpetic neuralgia




Fig. S6: Effect estimates of being eligible (A) and having received the zoster vaccine (B and C) on new diagnoses of dementia using local squared regression instead of local linear regression. 1,2,3,4,5


¹ Triangles (rather than points) depict our primary specification.

² Red (as opposed to white) fillings denote statistical significance (p<0.05).

³ With "grace periods" we refer to time periods since the index date after which follow-up time is considered to begin to allow for the time needed for a full immune response to develop after vaccine administration.

⁴ Grey vertical bars depict 95% confidence intervals.

⁵ Grey dots show the mean value for each 10-week increment in week of birth.







Fig. S7: No statistically significant effects of being eligible for the zoster vaccine on each of the ten (other than dementia) leading causes of disability-adjusted life years and mortality in Wales.^{1,2,3}

Abbreviations: Coef=coefficient; CI=confidence interval; COPD=chronic obstructive pulmonary disease

¹ These analyses used the same follow-up period (September 2 1933 to September 1 2020) as our primary analyses for dementia shown in the main manuscript.

² The analysis of breast cancer diagnoses was restricted to women only.

³ Grey dots show the mean value for each 10-week increment in week of birth.






Fig. S8: No statistically significant effects of being eligible for the zoster vaccine on preventive health actions. 1,2,3

¹ These analyses used the same follow-up period (September 2 1933 to September 1 2020) as our primary analyses with dementia as an outcome.

² Breast cancer screening participation was defined as having a record of referral to, attendance at, or a report from "breast cancer screening" or mammography. The analysis of breast cancer screening participation was restricted to women only.

³ Grey dots show the mean value for each 10-week increment in week of birth.




Fig. S9: The September 2 date-of-birth threshold only has an effect on the occurrence of dementia over a five-year follow-up period in the year (2013) for which that date was used as eligibility threshold for zoster vaccination. ^{1,2,3,4}

¹ This analysis implements the identical analysis as for September 1 2013 (the date on which the zoster vaccine program started), for September 1 of each of the three years prior to and after 2013. For example, when moving the start date of the program to "-2" (i.e., September 1 2011), we started the follow-up period on September 1 2011 and compared individuals around the September 2 1931 eligibility threshold. The purpose of this analysis is to verify that the day-month (i.e., September 2) cutoff used for zoster vaccine eligibility was not also used for other interventions that affect dementia risk.

² This analysis used a five-year follow-up period to allow each comparison to have the same length of follow-up.

³ White points depict statistically insignificant point estimates (p>0.05).

⁴ Grey vertical bars depict 95% confidence intervals.




Fig. S10: The September 2 date-of-birth threshold only has an effect on the occurrence of dementia over a seven-year follow-up period in the year (2013) for which that date was used as eligibility threshold for zoster vaccination.^{1,2,3}

¹ This analysis implements the identical analysis as for September 1 2013 (the date on which the zoster vaccine program started), for September 1 of each of the six years preceding 2013. For example, when moving the start date of the program to "-2" (i.e., September 1 2011), we started the follow-up period on September 1 2011 and compared individuals around the September 2 1931 eligibility threshold. The purpose of this analysis is to verify that the day-month (i.e., September 2) cutoff used for zoster vaccine eligibility was not also used for other interventions that affect dementia risk.

² White points depict statistically insignificant point estimates (p>0.05).

³ Grey vertical bars depict 95% confidence intervals.




Fig. S11: No effects on new diagnoses of dementia diagnosed in the seven years *prior* to the start of the zoster vaccine program (i.e., between September 1 2006 to August 31 2013).^{1,2,3,4,5,6}

¹ This figure shows the results from the identical analysis as implemented for our primary analysis (for which the results are shown in Fig. 3 in the main manuscript) except that we followed individuals from September 1 2006 to August 31 2013 instead of from September 1 2013 to August 31 2020. This analysis thus compares the exact same date-of-birth cohorts to each other and has the same length of follow-up as our primary analysis, but uses the seven years prior to the start of the zoster vaccine rollout as follow-up period instead of the seven years after program start. The purpose of this analysis is to verify that the same date-of-birth eligibility date used for zoster vaccine eligibility was not used for other interventions in the past that affect dementia risk.

² Triangles (rather than points) depict our primary specification.

³ Red (as opposed to white) fillings denote statistical significance (p<0.05).

⁴ With "grace periods" we refer to time periods since the index date after which follow-up time is considered to begin to allow for the time needed for a full immune response to develop after vaccine administration.

⁵ Grey vertical bars depict 95% confidence intervals.

⁶ Grey dots in Panel A show the mean value for each 10-week increment in week of birth.




Fig. S12: The magnitude of the abrupt change in vaccine uptake at the September 2 1933 date-of-birth eligibility threshold was similar between men and women.¹

¹ Grey dots show the mean value for each 10-week increment in week of birth. Abbreviations: Coef=coefficient; Cl=confidence interval




Fig. S13: Effect estimates of being eligible (A) and having received the zoster vaccine (B and C) on new diagnoses of dementia, taking into account the staggered roll-out and controlling for cohort fixed effects. 1,2,3,4,5,6

¹ Instead of starting the follow-up period for all individuals on September 1 2013, we adjusted the follow-up period to account for the staggered rollout of the program by beginning the follow-up period for each individual on the date on which they first became eligible for the zoster vaccine (see Methods for details). We added cohort fixed effects to these analyses to control for between cohort differences of the date at which the follow-up window started. That is, we defined one cohort fixed effect for ineligible individuals and the first catch-up cohort and included additional cohort fixed effects for each group of patients who became eligible at the same time.

² Triangles (rather than points) depict our primary specification.

³ Red (as opposed to white) fillings denote statistical significance (p<0.05).

⁴ With "grace periods" we refer to time periods since the index date after which follow-up time is considered to begin to allow for the time needed for a full immune response to develop after vaccine administration.

⁵ Grey vertical bars depict 95% confidence intervals.

⁶ Grey dots in Panel A show the mean value for each 10-week increment in week of birth.






Fig. S14: Histogram showing the number of individuals in our dataset by week of birth.¹

As detailed in the Methods, individuals in week 0 were excluded from our dataset because it was not possible to determine whether they fell above or below the date-of-birth eligibility threshold for the zoster vaccine program.









Fig. S15: Effect estimates of being eligible for the zoster vaccine on the probability of a new dementia diagnosis, having at least one shingles diagnosis, and having at least one diagnosis of postherpetic neuralgia across various follow-up periods. 1,2,3,4


¹ We show the same plots for the effect estimates of receipt of the zoster vaccine (as opposed to eligibility for the vaccine) in the main manuscript.

² White points depict statistically insignificant point estimates (p>0.05).

³ Grey vertical bars depict 95% confidence intervals.

⁴ Triangles (rather than points) depict our primary specification.








Fig. S16: Effect estimates of being eligible for the zoster vaccine on the probability of a new dementia diagnosis, having at least one shingles diagnosis, and having at least one diagnosis of postherpetic neuralgia across various grace periods. 1,2,3,4,5

¹ With "grace periods" we refer to time periods since the index date after which follow-up time is considered to begin to allow for the time needed for a full immune response to develop after vaccine administration.

² We show the same plots for the effect estimates of receipt of the zoster vaccine (as opposed to eligibility for the vaccine) in the main manuscript.

³ White points depict statistically insignificant point estimates (p>0.05).

⁴ Grey vertical bars depict 95% confidence intervals.

⁵ Triangles (rather than points) depict our primary specification.

Tables S1 to S4

Variable	%	N
Decile of Welsh Index of Multiple Deprivation, mean (SD)	5.8 (2.8)
1 (most deprived)	7.9	22,242
2	9.0	25,420
3	9.2	26,079
4	9.8	27,741
5	10.7	30,356
6	10.8	30,555
7	10.0	28,205
8	10.5	29,697
9	10.6	29,875
10 (least deprived)	11.5	32,347
Gender		
Male	45.4	128,322
Female	54.6	154,218
Clinical diagnoses		
Past shingles	12.2	34,540
Ischemic heart disease	16.3	46,025
Chronic obstructive pulmonary disease	11.9	33,511
Past stroke	7.6	21,454
Past lower respiratory tract infection	51.8	146,391
History of lung cancer	0.5	1,402
Past fall(s)	19.0	53,596
History of colorectal cancer	2.2	6,318
History of lower back pain	45.1	127,518
Diabetes mellitus	19.7	55,666
Uptake of preventive health measures		
Pneumococcal vaccine (PPV-23)	70.7	199,841
Recent statin use	43.6	123,200
Recent antihypertensive use	59.1	167,093

Table S1: Baseline characteristics of the cohort of individuals in our primary analyses for dementia (n=282,541). 1,2,3,4,5

¹ The baseline date was September 1 2013.

² Recent use of statins and antihypertensive drugs was defined as having received a prescription (whether new or repeat) of these medications within three months prior to September 1 2013.

³ The clinical codes for all diagnoses are shown in Text S1.

⁴ Deciles of the Welsh Index of Multiple Deprivation (WIMD) were calculated based on the 2011 WIMD survey².

⁵ 24 and 1 individuals had missing information for the WIMD and gender, respectively.

		Type of c	dementia	
	Any type	Alzheimer's	Vascular	Unspecified
	(1)	(2)	(3)	(4)
CACE (% points)	-3.5	-1.3	-1.1	-1.0
95% CI	(-7.1, -0.6)	(-3.8, 0.8)	(-3.2, 0.7)	(-3.1,1.0)
р	0.019	0.189	0.212	0.336
Relative effect (%)	-19.9	-17.9	-18.8	-19.1
Bandwidth (in weeks)	90.6	87.4	89.3	84.2
Observations	56,098	54,205	55,139	51,985
ITT (% points)	-1.3	-0.6	-0.3	-0.5
95% CI	(-2.7, -0.2)	(-1.7, 0.2)	(-1.2, 0.4)	(-1.3, 0.3)
р	0.022	0.11	0.36	0.193
Relative effect (%)	-8.5	-9.9	-6.1	-9.8
Bandwidth (in weeks)	134.4	108.1	115.3	132.0
Observations	83,167	66,933	71,440	81,484

Table S2: Effect estimates of being eligible and having received the zoster vaccine on new diagnoses of dementia, by type of dementia. The CACE (complier average causal effect) refers to the estimated effect of actually receiving the zoster vaccine rather than merely being eligible for the vaccine. The ITT (intent-to-treat) effect refers to the estimated effect of being eligible for the zoster vaccine. The bandwidth is the window (in weeks) in participants' date of birth that is drawn around the September 2 1933 eligibility threshold. We used mean-squared error (MSE) optimal bandwidths³. Observations refer to the numbers of observations within the MSE-optimal bandwidth.

Abbreviations: CACE=complier average causal effect (i.e., the estimated effect of actually receiving the zoster vaccine rather than merely being eligible for the vaccine); ITT=intent-to-treat effect (i.e., the estimated effect of being eligible for the zoster vaccine); CI=robust bias-corrected confidence interval; p=p value

		Type of				
	Any type	Alzheimer's	Vascular	Unspecified	Shingles	Postherpetic neuralgia
	(1)	(2)	(3)	(4)	(5)	(6)
Difference in CACE by gender	6.8	4.7	1.5	1.7	0.7	-0.4
95% CI	(1.2, 12.4)	(0.8, 8.5)	(-1.9, 5.0)	(-1.9, 5.2)	(-2.2, 3.7)	(-1.6, 0.9)
p	0.018	0.018	0.376	0.358	0.626	0.564
Bandwidth (in weeks)	90.6	87.4	89.3	84.2	116.9	96.6
Observations	56,098	54,205	55,139	51,985	76,316	63,039

Table S3: Difference (in percentage points) between women and men in the effect of receipt of the zoster vaccine on new diagnoses of dementia, having at least one shingles diagnosis, and having at least one diagnosis of postherpetic neuralgia. The CACE (complier average causal effect) refers to the estimated effect of actually receiving the zoster vaccine rather than merely being eligible for the vaccine. The reference group is women when calculating the difference in CACE. The difference in CACE by gender is estimated by running the following instrumental variable model:

$$Y_i = \alpha + \beta_1 V_i + \beta_2 \cdot (WOB_i - c_0) + \beta_3 D_i \cdot (WOB_i - c_0) + \beta_4 V_i \cdot MALE_i + \beta_5 \cdot (WOB_i - c_0) \cdot MALE_i + \beta_6 D_i \cdot (WOB_i - c_0) \cdot MALE_i + \epsilon_i$$

where i indexes the individual. Y is a binary variable equal to one if an individual experienced the outcome (i.e. a new dementia diagnosis, at least one shingles diagnosis, or at least one postherpetic neuralgia diagnosis). The binary variable V indicates receipt of the zoster vaccine. The binary variable D indicates eligibility for the zoster vaccine (it is, thus, equal to one if an individual was born on or after the cutoff date of September 2 1933). The binary variable MALE is equal to one if an individual is recorded as male in the electronic health record data. The term (WOB-C₀) indicates an individual's week of birth centered around the September 2 1933 eligibility date. The interaction term D*(WOB-C₀) allows for the slope of the regression line to differ on either side of the date-of-birth eligibility threshold. Adding the terms (WOB-C₀)*MALE and D*(WOB-C₀)*MALE allows the slopes to vary by gender. V and V*MALE are instrumented by D and D*MALE using two-stage least squares regression. The parameter β_4 identifies the gender difference in the effect of receipt of the vaccine on the outcome; this is the parameter reported in this table. Consistent with our primary regression discontinuity models shown in the main manuscript, we used local linear triangular kernel regressions and the MSE-optimal bandwidth sizes from the respective regression model (without interaction terms by gender) in our primary analysis. Observations refer to the number of observations within the optimal bandwidth.

Abbreviations: CACE=complier average causal effect (i.e., the estimated effect of actually receiving the zoster vaccine rather than merely being eligible for the vaccine); CI=confidence interval; p=p value

	Main Alternative o		nition of dementia	Restricted to frequent GP visitors	Controlled for health service utilization	Accounting for staggered roll- out	Quadratic fit
		by cause of death	by prescription				
	(1)	(2)	(3)	(4)	(5)	(6)	(7)
CACE	-3.5	-1.6	-1.9	-3.0	-3.3	-3.9	-3.8
95% CI	(-7.1, -0.6)	(-3.7, 0.2)	(-4.2, -0.1)	(-6.7, -0.2)	(-6.9, -0.5)	(-8.5, -0.6)	(-7.5, -0.8)
p	0.019	0.073	0.044	0.036	0.023	0.023	0.015
ITT	-1.3	-0.8	-0.8	-1.2	-1.2	-1.2	-1.8
95% CI	(-2.7, -0.2)	(-1.8, -0.1)	(-1.7, -0.1)	(-2.8, 0.1)	(-2.6, -0.1)	(-2.7, -0.1)	(-3.6, -0.3)
p	0.022	0.031	0.02	0.059	0.028	0.041	0.017
N	282,541	282,541	282,541	237,196	282,541	263,475	282,541

Table S4: Additional robustness checks. The CACE (complier average causal effect) refers to the estimated effect of actually receiving the zoster vaccine rather than merely being eligible for the vaccine. The ITT (intent-to-treat) effect refers to the estimated effect of being eligible for the zoster vaccine.

- In (1), we show the results from our primary analysis for comparison (i.e., the identical results as shown in Fig. 3 in the main manuscript). In each of the other columns, we implemented the identical analysis as for our primary analysis, except for the following differences.
- In (2), we defined dementia solely as dementia being named a primary or contributory cause of death on the death certificate.
- In (3), we defined dementia solely as a new prescription of donepezil hydrochloride, galantamine, rivastigmine, memantine hydrochloride, or idebenone.
- In (4), we restricted the analysis cohort to only those individuals who had visited their primary care provider at least once in each of the five years preceding the start date of the zoster vaccine program.
- In (5), we adjusted our regressions for the following indicators of health service utilization during the follow-up period: the probability of receiving at least one influenza vaccination and the number of i) primary care visits, ii) outpatient visits, and iii) hospital admissions.
- In (6), instead of using September 1 2013 as the index date, we set the index date as the date when each date-of-birth cohort first became eligible for the zoster vaccine (see Methods for details) and adjusted our regressions for cohort fixed effects. These results are also shown in Fig. S8.
- In (7), we used local squared regression instead of local linear regression. These results are also shown in Fig. S10.

Abbreviations: CACE=complier average causal effect (i.e., the estimated effect of actually receiving the zoster vaccine rather than merely being eligible for the vaccine); CI=robust bias-corrected confidence interval; p=p value; ITT=intent-to-treat effect (i.e., the estimated effect of being eligible for the zoster vaccine); N=sample size; GP=general practitioner

References

- 1. Calonico, S., Cattaneo, M. D. & Titiunik, R. Robust Nonparametric Confidence Intervals for Regression-Discontinuity Designs. *Econometrica* **82**, 2295–2326 (2014).
- Statistical Directorate. Welsh Index of Multiple Deprivation 2011: Summary Report.
 https://www.gov.wales/welsh-index-multiple-deprivation-full-index-update-ranks-2011 (2011).
- 3. Imbens, G. & Kalyanaraman, K. Optimal Bandwidth Choice for the Regression Discontinuity Estimator. *The Review of Economic Studies* **79**, 933–959 (2012).